Related Experiment Video

Updated: Jun 23, 2026

Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer
06:51

Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer

Published on: July 21, 2018

[Targeting of the AKT-mTOR pathway in head and neck and lung cancer]

S Vignot1, S Haberer, B Besse

  • 1Service d'Oncologie Médicale, Groupe Hospitalier de La Pitié-Salpêtrière, 45 Boulevard de l'Hôpital, 75013 Paris, France. svignot@hopital-dcss.org

Bulletin Du Cancer
|May 13, 2009
PubMed

Insights

The AKT-mTOR pathway regulates cell metabolism and immunity. mTOR inhibitors, initially for immune modulation, are now targeted therapies for solid tumors and lymphomas, showing promise for head and neck or pulmonary cancers.

Area of Science:

  • Oncology
  • Immunology
  • Molecular Biology

Background:

  • The AKT-mTOR pathway is crucial for cell metabolism, immune response, and cancer development.
  • mTOR inhibitors have emerged as targeted therapies for various cancers, including lymphomas and solid tumors.

Purpose of the Study:

  • To review the role of the AKT-mTOR pathway in cancer.
  • To synthesize current data on mTOR inhibitors for head and neck and pulmonary tumors.
  • To discuss the potential future development of mTOR inhibitors.

Main Methods:

  • Literature review of preclinical and clinical data.
  • Synthesis of existing knowledge on the AKT-mTOR pathway.
  • Analysis of therapeutic strategies involving mTOR inhibitors.

Main Results:

  • The AKT-mTOR pathway's intricate network influences cell metabolism and immune regulation.
  • mTOR inhibitors demonstrate therapeutic potential in non-hematologic solid tumors and lymphomas.
  • Emerging data suggests value for mTOR inhibitors in head and neck and pulmonary cancers.

Conclusions:

  • The AKT-mTOR pathway is a significant target in oncology.
  • mTOR inhibitors represent a promising targeted therapy class.
  • Further research into mTOR inhibitors for head and neck and pulmonary cancers is warranted.

More Related Videos

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts10:27

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts

Published on: July 25, 2020

Multi-photon Imaging of Tumor Cell Invasion in an Orthotopic Mouse Model of Oral Squamous Cell Carcinoma12:03

Multi-photon Imaging of Tumor Cell Invasion in an Orthotopic Mouse Model of Oral Squamous Cell Carcinoma

Published on: July 25, 2011

Related Concept Videos

mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a rapamycin-insensitive companion...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...